Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2004

View Archived Issues

New modulators of farnesoid X receptors covered by X-Ceptor patent

Novel FAP-activated prodrugs with utility in cancer therapy

Kowa describes new PPARalpha agonists, their preparation and use

Yamanouchi patents novel ApoB-related lipoprotein secretion inhibitors

Bayer scientists claim new pyrimidine-based antiproliferative agents

Update on Generex technologies

Enrollment stopped in phase II of Velcade for metastatic colorectal cancer

FDA approval for Invirase boosted with ritonavir for HIV

Restructuring at D-Pharm completed

GT-1061 advances into phase I safety study for Alzheimer's

U.S. enrollment commences for phase II SDX-105 study

BCY Lifesciences seeking partner or licensee for DCF-987

Zavesca launched in U.S.

Dosing commences in pivotal PRECIS-1 study of CDP-870 for Crohn's disease

Chemokine Therapeutics files for U.S. orphan drug designation for CTCE-9908

Andrx and Takeda to develop Actos/Fortamet combination product

Organon pays Cortex milestone to retain AMPAKINE technology rights

Long-term effectiveness of olanzapine and haloperidol in schizophrenia

ISV-205 limits IOP increase induced by corticosteroids

Long-term use of lipid-lowering drugs reported to improve when started in an inpatient setting

A new phase II clinical trial to evaluate two furosemide formulations in CHF patients

Oxycyte(TM) to enter phase II testing during 2004

Tularik's T-131 is being assessed in patients with type 2 diabetes

Dynogen Pharmaceuticals announces collaboration with Johnson & Johnson

Corixa Corporation announces NIH biodefense partnership

Aventis Pharma and Avalon Pharmaceuticals form collaboration

XenoPort announces collaboration with Pfizer

PCALC-36, a new Na+/K+-ATPase inhibitor with a unique mechanism of action

Primaquine derivative shows good antimalarial activity and less toxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...